Low-flow ECCO2R for ICU patients with respiratory failure: safety and outcomes
Retrospective Cohort Study of Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) System: Evaluating Efficacy and Safety
Hong Kong University · NCT07161271
This review looks back at adults in the ICU who received low-flow ECCO2R to see if the treatment was safe and helped people with respiratory failure, including ARDS and severe asthma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 59 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hong Kong University (other) |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07161271 on ClinicalTrials.gov |
What this trial studies
This is a retrospective chart review of adult patients treated with low-flow extracorporeal carbon dioxide removal (ECCO2R) at Queen Mary Hospital between January 1, 2022 and June 30, 2024. The team will describe which patients were selected for ECCO2R, specific technical and clinical management choices, and short-term clinical outcomes and adverse events. Data will be drawn from routinely collected ICU records to characterize practice patterns and complications associated with low-flow systems. The goal is to identify factors that could improve the quality and safety of ECCO2R use in critically ill patients.
Who should consider this trial
Good fit: Adults (18 years or older) who were admitted to the ICU at Queen Mary Hospital and received low-flow ECCO2R between January 1, 2022 and June 30, 2024 are the subjects of this review.
Not a fit: Patients who were not treated with ECCO2R, treated at other hospitals, or under 18 years old would not be represented and so would not directly benefit from the study's conclusions.
Why it matters
Potential benefit: If findings show favorable safety and outcomes, clinicians could better select patients and manage low-flow ECCO2R to reduce complications and improve ICU care.
How similar studies have performed: Previous small trials of ECCO2R have produced physiological benefits such as reduced ventilator intensity but have not consistently shown improved mortality, and low-flow systems remain less well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients supported with ECCO2R in one of the designated study sites * Admitted to the ICU between 1 Jan 2022 and 30 June 2024 Exclusion Criteria: * Patients younger than 18 years old
Where this trial is running
Hong Kong
- Queen Mary Hospital (QMH) — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Study coordinator: Wai Ching Simon Sin, Director, Clinical Professor
- Email: drwcsin@hku.hk
- Phone: (852)9090-8772
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Respiratory Failure, ICU, Asthma, ARDS, ECCO2R, Respiratory failure